{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:11:52Z","timestamp":1767211912733,"version":"3.32.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.cyto.2023.156401","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T23:02:55Z","timestamp":1697065375000},"page":"156401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effect of interleukin-2 (IL-2) polymorphisms on multiple myeloma: IL-2RA rs2104286, IL-2 rs2069762 and rs2069763 polymorphisms"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1855-774X","authenticated-orcid":false,"given":"Istemi","family":"Serin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasin","family":"Colak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasemin","family":"Oyaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima Ceren","family":"Tuncel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sacide","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2023.156401_b0005","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cyto.2023.156401_b0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.cyto.2023.156401_b0015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas - current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cyto.2023.156401_b0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cyto.2023.156401_b0025","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Bergsagel","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.cyto.2023.156401_b0030","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2023.156401_b0035","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1470-2045(03)01195-1","article-title":"New insights into the pathophysiology of multiple myeloma","volume":"4","author":"Seidl","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cyto.2023.156401_b0040","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.4049\/jimmunol.171.11.5727","article-title":"IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion","volume":"171","author":"D'Souza","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2023.156401_b0045","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2147\/OTT.S94761","article-title":"Association between two interleukin-2 gene polymorphisms and cancer susceptibility: a meta-analysis","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets."},{"key":"10.1016\/j.cyto.2023.156401_b0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1744-313X.2005.00502.x","article-title":"Cytokine gene polymorphism in Iranian patients with chronic myelogenous leukaemia","volume":"32","author":"Amirzargar","year":"2005","journal-title":"Int. J. Immunogenet."},{"key":"10.1016\/j.cyto.2023.156401_b0055","first-page":"159","article-title":"IL1beta+3953 exon 5 and IL-2 -330 promoter polymorphisms in patients with rheumatoid arthritis","volume":"23","author":"Pawlik","year":"2005","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.cyto.2023.156401_b0060","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1089\/dna.2011.1476","article-title":"The association between -330T\/G polymorphism of interleukin 2 gene and bladder cancer","volume":"31","author":"Shen","year":"2012","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.cyto.2023.156401_b0065","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1089\/gtmb.2012.0494","article-title":"Interleukin-2 gene polymorphisms and prognosis of breast cancer","volume":"17","author":"Hu","year":"2013","journal-title":"Genet. Test. Mol. Biomarkers"},{"key":"10.1016\/j.cyto.2023.156401_b0070","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1089\/dna.2011.1603","article-title":"Interleukin 2 gene polymorphisms are associated with non-Hodgkin lymphoma","volume":"31","author":"Song","year":"2012","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.cyto.2023.156401_b0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/bmm.15.113","article-title":"Clinical significance of IL-2 and IL-10 gene polymorphisms and serum levels in patients with basal-cell carcinoma","volume":"10","author":"Sobjanek","year":"2016","journal-title":"Biomark. Med."},{"key":"10.1016\/j.cyto.2023.156401_b0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4049\/jimmunol.1200301","article-title":"IL-2 requirement for human plasma cell generation: coupling differentiation and proliferation by enhancing MAPK-ERK signaling","volume":"189","author":"Le Gallou","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2023.156401_b0085","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s12288-020-01388-4","article-title":"The Influence of Interleukin-2 Gene Polymorphisms on the Risk and Clinical Outcome of Non-Hodgkin Lymphoma","volume":"37","author":"Mousa","year":"2021","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"10.1016\/j.cyto.2023.156401_b0090","first-page":"69:35","article-title":"Zeinab Sabri Mohammed and Naglaa Fathy Barseem. PTPN22 gene and IL2RA rs11594656, rs2104286 gene variants: additional insights of polygenic single-nucleotide polymorphisms\u2019 pattern among Egyptian children with type 1 diabetes","author":"Abou","year":"2021","journal-title":"Egypt Pediatric Association Gaz."},{"key":"10.1016\/j.cyto.2023.156401_b0095","first-page":"1852517","article-title":"Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma","author":"Musolino","year":"2017","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.cyto.2023.156401_b0100","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.bmt.1704670","article-title":"Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives","volume":"34","author":"Zeiser","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.cyto.2023.156401_b0105","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1097\/00007890-200110270-00019","article-title":"Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3\/CD28-stimulated peripheral blood lymphocytes","volume":"72","author":"Hoffmann","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.cyto.2023.156401_b0110","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2147\/OTT.S86136","article-title":"IL-2 -330T\/G polymorphism and cancer risk: a meta-analysis","volume":"8","author":"Zhao","year":"2015","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.cyto.2023.156401_b0115","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7314\/APJCP.2012.13.2.621","article-title":"Genetic variants in interleukin-2 and risk of lymphoma among children in Korea","volume":"13","author":"Song","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.cyto.2023.156401_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.816499","article-title":"Natural Killer Cells in the Malignant Niche of Multiple Myeloma","volume":"12","author":"Venglar","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104346662300279X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104346662300279X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T10:08:49Z","timestamp":1736417329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104346662300279X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":24,"alternative-id":["S104346662300279X"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156401","relation":{},"ISSN":["1043-4666"],"issn-type":[{"type":"print","value":"1043-4666"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of interleukin-2 (IL-2) polymorphisms on multiple myeloma: IL-2RA rs2104286, IL-2 rs2069762 and rs2069763 polymorphisms","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156401"}}